Clin2
NCT06782724Possibly a fitRecruiting

Psilocybin therapy for distress in advanced illness

COPD (Chronic Obstructive Pulmonary Disease)ALS (Amyotrophic Lateral Sclerosis)MS (Multiple Sclerosis)Major Depressive Disorder (MDD)Atypical Parkinson Disease

Part of Brain & nervous system, Hormones & metabolism, Immune system & allergy, Lungs & breathing, Mental health clinical trials.

This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
108 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have one of these serious illnesses: COPD, ALS, MS, or advanced Parkinson's disease (or a similar disorder).
  • You have been diagnosed with major depression and it's been bothering you.
  • You are at least 18 years old and a family member or friend can be your support person.
  • You have not taken any psychedelic drugs in the last 6 months.
  • You are not currently at high risk for suicide, and you do not have a history of schizophrenia or bipolar disorder.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07405606Not yet recruiting· Phase 2
Psilocybin therapy for depression and alcohol use disorder

This study tests whether a drug called psilocybin, given along with therapy, can help people who have both major depression and alcohol use disorder. You may be a good fit if you have tried other treatments or don't want to start new medications.

Toronto, Ontario
NCT06656702Recruiting· Early Phase 1
Psilocybin for depression in amyotrophic lateral sclerosis

This trial tests whether psilocybin, a psychedelic drug, can safely help with depression in people with ALS. It also looks at how the drug affects your symptoms and quality of life over six months.

Baltimore, Maryland
NCT07063862Recruiting· Phase 3
Psychedelic microdose for emotional distress in advanced illness

This trial tests whether very low doses of psilocybin (a psychedelic substance) can help reduce emotional distress in people with a life-limiting illness. If you are receiving palliative care and feeling anxious or depressed, this study might offer a way to explore a new treatment option.

Brampton, Ontario
NCT06818994Recruiting· Phase 1
Psilocybin therapy for low mood in advanced cancer

This trial tests if a medicine called psilocybin, given with talk therapy, can safely help people with advanced cancer who feel very demoralized. Demoralization is a deep sense of hopelessness or loss of meaning. The goal is to see if this treatment can improve your emotional well-being.

Kingston, Ontario
NCT06200155Recruiting· Phase 2
Psilocybin therapy for advanced cancer patients with anxiety or depression

This trial tests whether a drug called psilocybin, given with therapy, can help people with advanced cancer who are feeling anxious or depressed. You must have a stable cancer and be willing to travel to Houston for treatment.

Houston, Texas
NCT07216404Recruiting· Phase 2
Psilocybin therapy for depression in lung cancer patients

This trial tests whether a psychedelic-assisted therapy can help treat major depression in people with non-small cell lung cancer. If you have moderate to severe depression and are receiving cancer treatment, you may be able to join.

Columbus, Ohio

Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.